Early detection and monitoring of adverse drug reactions (ADRs) can minimize the deleterious impact on patients and health-care systems (Hakkarainen et al., 2012;Sultana et al., 2013 For prevention, the drug safety organizations known as pharmacovigilance agencies conduct post-market surveillance to identify the drug's side effects post-release.
the majority of the existing ADE surveillance systems utilizes passive spontaneous reporting system databases, such as the Federal Drug Administration's Adverse Event Reporting System (FAERS) (Li et al., 2014).